CLD18A2-Targeted CAR Effector Cells to Reduce Off-Target Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chimeric antigen receptor (CAR) T lymphocyte therapies face challenges such as off-target effects, cytokine storms, and difficulty in selecting suitable tumor-specific antigens, leading to unsatisfactory therapeutic outcomes and potential tissue damage.
Innovation Solution
Development of a CAR targeting CLD18A2, comprising a specific extracellular binding region, transmembrane region, and intracellular signaling region, expressed on immune effector cells like T lymphocytes, using single-chain antibodies and intracellular signaling molecules like CD3ζ and CD28 to enhance tumor specificity and cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T lymphocytes are designed with strong tumor-targeting capability, then anti-tumor specificity is improved, but off-target effects and tissue damage increase
Solution Approach 1:
The patent applies local quality by selecting CLD18A2 as a tumor-specific antigen that is locally expressed in pancreatic and gastric cancer cells, while avoiding expression in normal tissues. This localized antigen selection enables the CAR T cells to specifically target tumor cells without attacking healthy tissues, thereby improving anti-tumor specificity while reducing off-target effects.
Solution Approach 2:
The patent changes the parameter of antigen selection from generic tumor markers to specifically CLD18A2, which has distinct expression patterns in tumor versus normal tissues. This parameter change allows the CAR T cells to differentiate between tumor and normal cells based on the unique expression profile of CLD18A2, achieving high specificity with minimal off-target toxicity.
2Reliability
If CAR T lymphocytes are engineered with high cytotoxicity, then tumor killing ability is improved, but cytokine storm risk increases
Solution Approach 1:
The patent incorporates co-stimulatory signaling domains (CD28, CD137) into the CAR structure, creating a feedback mechanism where the receptor provides both activation and regulatory signals. This dual signaling approach enables controlled tumor cell killing while regulating cytokine release, preventing excessive immune activation that would lead to cytokine storms.
Solution Approach 2:
The patent uses composite CAR structures combining multiple signaling domains (CD3ζ for activation, CD28/CD137 for co-stimulation) within a single receptor molecule. This composite design integrates multiple functional elements to achieve balanced cytotoxicity and regulatory responses, preventing runaway immune activation while maintaining effective tumor killing.
3Duration of action of moving object
If multiple co-stimulatory domains are included in CAR, then T cell proliferation and survival are improved, but CAR complexity increases
Solution Approach 1:
The patent segments the CAR structure into distinct functional modules: extracellular binding domain (scFv), transmembrane region, and intracellular signaling domains (CD3ζ, CD28, CD137). This segmentation allows each domain to perform its specific function independently while being assembled into a unified CAR structure, making the complex multi-domain receptor manageable and modular for design and production.
Data Source
AI summary
Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.